REVB - Revere Bank Stock Price, Fair Value and News

$0.29-0.02 (-6.45%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

REVB Price Action

Last 7 days

-19.4%

Last 30 days

-61.8%

Last 90 days

-65.5%

Trailing 12 Months

-98.3%

REVB RSI Chart

REVB Valuation

Market Cap

1.2M

Price/Earnings (Trailing)

-0.08

Price/Sales (Trailing)

180.51

Price/Free Cashflow

-0.07

REVB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

REVB Fundamentals

REVB Revenue

Revenue (TTM)

6.9K

REVB Earnings

Earnings (TTM)

-15.5M

Earnings Growth (Yr)

14.72%

Earnings Growth (Qtr)

73.28%

REVB Profitability

Return on Equity

-580.33%

Return on Assets

-230.2%

Free Cashflow Yield

-1.3K%

REVB Investor Care

Shares Dilution (1Y)

1944.90%

Diluted EPS (TTM)

-24.3

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	2.9K	4.2K	5.6K	6.9K
2020	0	0	0	1.6K

Get all data in R, Python etc through our Historical Stock Data APIs

About Revere Bank

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

CEO	Mr. James M. Rolke
WEBSITE	revbiosciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	6

Revere Bank Frequently Asked Questions

What is the ticker symbol for Revere Bank? What does REVB stand for in stocks?

REVB is the stock ticker symbol of Revere Bank. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Revere Bank (REVB)?

As of Fri Dec 20 2024, market cap of Revere Bank is 1.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REVB stock?

You can check REVB's fair value in chart for subscribers.

Is Revere Bank a good stock to buy?

The fair value guage provides a quick view whether REVB is over valued or under valued. Whether Revere Bank is cheap or expensive depends on the assumptions which impact Revere Bank's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REVB.

What is Revere Bank's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, REVB's PE ratio (Price to Earnings) is -0.08 and Price to Sales (PS) ratio is 224.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REVB PE ratio will change depending on the future growth rate expectations of investors.